Heart rate variability of elite female rowers in preparation for and during the national selection regattas: a pilot study on the relation to on water performance.

Elite athletes require a delicate balance of physiological and psychological stress and recovery-essential for achieving optimal performance. Monitoring heart rate variability (HRV) provides a non-invasive estimation of both physiological and psychological stress levels, offering potentially valuable insights into health, performance, and adaptability. Previous studies, primarily conducted on male participants, have shown an association between HRV and performance in the context of rowing training. However, given the rigorous nature of rowing training, it is crucial to investigate HRV in elite rowers, particularly during the U.S. national selection regattas (NSR). Purpose: To comprehensively analyze elite female rowers, evaluating acute changes in HRV and subjective psychometrics during the NSR. Methods: Five elite female rowers (26 ± 2 years, 180 ± 8 cm, 82 ± 8 kg, 19 ± 6%fat) were recruited and tracked prior to and during NSR I and II. Morning HRV measures were completed using photoplethysmography (HRV4training) along with self-reported levels of fatigue, soreness, rating of perceived exertion, mentally energy and physical condition. Results: Significant decreases were observed in log transformed root-mean square of successive differences (LnRMSSD; p = 0.0014) and fatigue (p = 0.01) from pre-to-during NSR, while mental energy (p = 0.01), physical condition (p = 0.01), and motivation (p = 0.006) significantly increased. These psychometric measures returned to pre-NSR levels, at post-NSR (all p < 0.05), though HRV remained slightly suppressed. NSR on-water performance was not correlated to LnRMSSD or the change in LnRMSSD (p > 0.05). Discussion: HRV and psychometric measures are sensitive to the stress of elite rowing competition in females. However, HRV was not associated with on-water rowing performance during an elite rowing competition.

Intermittent fasting two days versus one day per week, matched for total energy intake and expenditure, increases weight loss in overweight/obese men and women.

BACKGROUND: Intermittent fasting (IF), consisting of either a one-day (IF1) or two consecutive days (IF2) per week, is commonly used for optimal body weight loss. Our laboratory has previously shown an IF1 diet combined with 6d/week of protein pacing (P; 4-5 meals/day evenly spaced, ~ 30% protein/day) significantly enhances weight loss, body composition, and cardiometabolic health in obese men and women. Whether an IF1-P or IF2-P, matched for weekly energy intake (EI) and expenditure (EE), is superior for weight loss, body composition, and cardiometabolic health is unknown. METHODS: This randomized control study directly compared an IF1-P (n = 10) versus an IF2-P (n = 10) diet on weight loss and body composition, cardiovascular (blood pressure and lipids), hormone, and hunger responses in 20 overweight men and women during a 4-week weight loss period. Participants received weekly dietary counseling and monitoring of compliance from a registered dietitian. All outcome variables were assessed pre (week 0) and post (week 5). RESULTS: Both groups significantly reduced body weight, waist circumference, percent body fat, fat mass, hunger, blood pressure, lipids, glucose, and increased percent fat-free mass (p < 0.05). However, IF2-P resulted in significantly greater reductions in body weight (-29%) and waist circumference (-38%) compared to IF1-P (p < 0.05), and showed a strong tendency for greater reductions in fat mass, glucose, and hunger levels (p < 0.10) despite similar weekly total EI (IF1-P, 9058 ± 692 vs. IF2-P, 8389 ± 438 kcals/week; p = 0.90), EE (~ 300 kcals/day; p = 0.79), and hormone responses (p > 0.10). CONCLUSIONS: These findings support short-term IF1-P and IF2-P to optimize weight loss and improve body composition, cardiometabolic health, and hunger management, with IF2-P providing enhanced benefits in overweight women and men. TRIAL REGISTRATION: This trial was registered March 03, 2020 at www. CLINICALTRIALS: gov as NCT04327141 .